Certara, Inc. (CERT) Form 10-Q — Nov 5, 2026
Certara reported Q3 2026 revenue of $94.9 million, up 4% year over year, driven by 11% growth in software revenue to $48.8 million, while services revenue slipped 2% to $46.1 million. The company posted GAAP net income of $5.6 million ($0.04 basic EPS) and adjusted EBITDA of $30.2 million for the quarter. The nine-month picture is messier: continuing-ops net loss widened to $21.5 million from $1.8 million a year ago, largely on a $56.7 million pretax loss tied to the completed May 2026 sale of the Regulatory and Medical Writing business to Veristat. Certara has received $78.2 million in cash and is eligible for an earn-out of up to $35 million.
Key figures
- Eps
- 0.04
- Revenue
- 94901000
- Net Income
- 5592000
- Total Debt
- 293288000
- Revenue Yoy
- 4%
- Total Assets
- 1414918000
- Cash Position
- 214932000
- Shares Outstanding
- 152543402
- Goodwill
- 716416000
- Nine month revenue
- 282264000
- Q3 adjusted ebitda
- 30209000
- Pretax loss on sale
- 56700000
- Q3 services revenue
- 46069000
- Q3 software revenue
- 48832000
- Q3 bookings millions
- 92.5
- Q3 net retention rate
- 106.8%
- Q3 adjusted diluted eps
- 0.09
- Q3 services revenue yoy
- -2%
- Q3 software revenue yoy
- 11%
- Divestiture cash received
- 78200000
- Divestiture earnout up to
- 35000000
- Buyback remaining new program
- 50000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.